Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

30 Oct 2025 15:30

RNS Number : 5625F
GSK PLC
30 October 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.8395

 

 

37,000

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-10-29

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.8865

 

 

 

120,000

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-10-29

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFDUFLSEISEIS
Date   Source Headline
12th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation
11th Aug 202211:51 amRNSDirector/PDMR Shareholding
10th Aug 20224:57 pmRNSDirector/PDMR Shareholding
1st Aug 20226:10 pmRNSTotal Voting Rights
1st Aug 20221:43 pmRNSDirector/PDMR Shareholding
29th Jul 20222:00 pmRNSDirector/PDMR Shareholding
29th Jul 202210:00 amRNSGSK Board change
28th Jul 20221:01 pmRNSDirector/PDMR Shareholding
27th Jul 20227:00 amRNS2nd Quarter Results
26th Jul 20225:35 pmRNSHolding(s) in Company
22nd Jul 20224:45 pmRNSHolding(s) in Company
22nd Jul 20224:17 pmRNSBoard and Committee Changes
19th Jul 20227:00 amRNSCompletion of GSK Share Consolidation
18th Jul 20226:00 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSHaleon demerger completion and share consolidation
12th Jul 20229:48 amRNSDirector/PDMR Shareholding
11th Jul 20225:30 pmRNSGSK
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine
9th Jun 20224:28 pmRNSDirector/PDMR Shareholding
7th Jun 20225:17 pmRNSDirector/PDMR Shareholding
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix
1st Jun 20224:55 pmRNSTotal Voting Rights
1st Jun 20221:00 pmRNSDemerger update: Publication of Documents
1st Jun 20227:00 amRNSDemerger update: Submission of Documents to FCA
31st May 20227:00 amRNSGSK to acquire Affinivax, Inc.
30th May 202210:00 amRNSFurther appointments to Designate Haleon Board
27th May 20227:00 amRNSGSK Cervarix two-dose schedule approved by NMPA
25th May 20223:41 pmPRNDirector/PDMR Shareholding
23rd May 20223:21 pmRNSDirector/PDMR Shareholding
19th May 202210:02 amRNSIain Mackay - External Appointment
16th May 20222:00 pmRNSChange of name to GSK plc
13th May 20225:13 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.